<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776347</url>
  </required_header>
  <id_info>
    <org_study_id>OSK-08096</org_study_id>
    <nct_id>NCT00776347</nct_id>
  </id_info>
  <brief_title>Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)</brief_title>
  <official_title>Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil&#xD;
      therapy and to associate change of glucose metabolism and symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FDG-PET</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function, psychiatric symptoms, global clinical function, and burden of caregiver</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dementia With Lewy Bodies (DLB)</condition>
  <arm_group>
    <arm_group_label>donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks</description>
    <arm_group_label>donepezil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <arm_group_label>donepezil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DLB patients:&#xD;
&#xD;
          -  who fulfill the diagnostic criteria of DLB&#xD;
&#xD;
          -  60 to 85 years old&#xD;
&#xD;
          -  right-handed&#xD;
&#xD;
          -  Clinical Dementia Rating (CDR) â‰§ 0.5&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE) score from 10 to 26&#xD;
&#xD;
        Normal Controls:&#xD;
&#xD;
          -  who are independent&#xD;
&#xD;
          -  who have no subjective or objective cognitive impairment&#xD;
&#xD;
          -  60 to 85 years old&#xD;
&#xD;
          -  right-handed&#xD;
&#xD;
          -  MMSE score over 24&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        DLB patients:&#xD;
&#xD;
          -  who have diabetes mellitus&#xD;
&#xD;
          -  who have pathological change on MRI other than brain atrophy&#xD;
&#xD;
          -  who have complication or history of dementia other than DLB, psychiatric disease, and&#xD;
             physical disorder that affect brain function&#xD;
&#xD;
          -  who have severe complication of cardiovascular, hepatic, renal, or other diseases&#xD;
             unable to secure the safety&#xD;
&#xD;
          -  who have severe digestive ulcus&#xD;
&#xD;
          -  who have severe bronchitic asthma or obstructive lung disease&#xD;
&#xD;
          -  who have no caregiver who knows patient's condition well&#xD;
&#xD;
        Normal Controls:&#xD;
&#xD;
          -  who have diabetes mellitus&#xD;
&#xD;
          -  who have taken donepezil before&#xD;
&#xD;
          -  who have abnormal findings on MRI&#xD;
&#xD;
          -  who have complication or history of brain injury, psychiatric disease, and physical&#xD;
             disorder that affect brain function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Kazui, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita,</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.med.osaka-u.ac.jp/index-e.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Hiroaki Kazui</investigator_full_name>
    <investigator_title>M.D,Ph.D</investigator_title>
  </responsible_party>
  <keyword>Dementia with Lewy bodies (DLB)</keyword>
  <keyword>FDG-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

